Literature DB >> 6280204

Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats.

B K Colasanti, C Lindamood, C R Craig.   

Abstract

Rats rendered chronically epileptic by bilateral implantation of cobalt into frontal cortices were simultaneously prepared with permanent electrodes for longitudinal recording of the electroencephalogram (EEG) and electromyogram (EMG). Delta-8-tetrahydrocannabinol (delta-8-THC; 10 mg/kg), delta-9-tetrahydrocannabinol (delta-9-THC; 10 mg/kg), cannabidiol (CBD; 60 mg/kg), or polyvinylpyrrolidone (PVP) vehicle (2 ml/kg) was administered IP twice daily from day 7 through 10 after cobalt implantation, at which time generalized seizure activity in non-treated cobalt-epileptic rats was maximal. Relative to PVP-treated controls, CBD did not alter the frequency of appearance of seizures during the course of repeated administration. In contrast, both delta-8-THC and delta-9-THC markedly reduced the incidence of seizures on the first and second days of administration. Interictal spiking during this period, on the other hand, was actually enhanced. On the third and fourth days, tolerance to the effect on seizures was evident, with a return of seizure frequency of THC-treated rats to values not significantly different from those of controls. Unlike the effect on seizures, no tolerance developed to the marked suppression of rapid eye movement (REM) sleep induces by delta-8-THC and delta-9-THC. REM sleep remained reduced in the treated animals during the first 2 days after termination of THC administration. In contrast, REM sleep time was unaffected by repeated administration of CBD. These results suggest that delta-8-THC and delta-9-THC exert their initial anticonvulsant effect by limiting the spread of epileptogenic activity originating from the cobalt focus.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6280204     DOI: 10.1016/0091-3057(82)90418-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  14 in total

1.  Marijuana use and the risk of new onset seizures.

Authors:  J C Brust; S K Ng; A W Hauser; M Susser
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

Review 2.  Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signaling.

Authors:  Yuki Sugaya; Masanobu Kano
Journal:  Cell Mol Life Sci       Date:  2018-05-08       Impact factor: 9.261

Review 3.  Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Authors:  Orrin Devinsky; Maria Roberta Cilio; Helen Cross; Javier Fernandez-Ruiz; Jacqueline French; Charlotte Hill; Russell Katz; Vincenzo Di Marzo; Didier Jutras-Aswad; William George Notcutt; Jose Martinez-Orgado; Philip J Robson; Brian G Rohrback; Elizabeth Thiele; Benjamin Whalley; Daniel Friedman
Journal:  Epilepsia       Date:  2014-05-22       Impact factor: 5.864

4.  Interactions between cannabidiol and Δ9 -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome.

Authors:  Lyndsey L Anderson; Ivan K Low; Iain S McGregor; Jonathon C Arnold
Journal:  Br J Pharmacol       Date:  2020-07-27       Impact factor: 8.739

Review 5.  Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.

Authors:  Evan C Rosenberg; Pabitra H Patra; Benjamin J Whalley
Journal:  Epilepsy Behav       Date:  2017-02-09       Impact factor: 2.937

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

7.  Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.

Authors:  Rafael G Dos Santos; Jaime E C Hallak; José Alexandre S Crippa
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 9.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 10.  Pediatric Concerns Due to Expanded Cannabis Use: Unintended Consequences of Legalization.

Authors:  George Sam Wang
Journal:  J Med Toxicol       Date:  2016-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.